Novo Nordisk a S (NVO)
Novo Nordisk makes and sells medicines for obesity, diabetes and rare diseases, and is based in Denmark. It last closed at $37.82 on Nov 20, down 2.70% on the day.
Key Stats
Fiscal 2025Not reported for this period.
From NVO's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Feb 4). Figures are in DKK. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on NVO
Technical AnalysisPrices may be delayed
The stock is 6% below its 20 day and 5% below its 50 day average. It is 13% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 38), near oversold. The nearest support is the Pivot S1 at $37.34, and the nearest resistance the Pivot at $38.23.
| RSI (14) | 38.01 | Weak, oversold below 30 | Neutral |
| MACD | -0.10 | Below its signal line | Bearish |
| Stochastic | 3.2 | Near the bottom of its range | Oversold |
| ADX (14) | 16.6 | No clear trend | |
| Williams %R | -98.7 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -139.3 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −6.2% | Change over 10 sessions | Bearish |
| ATR (14) | $1.13 | Typical daily range, 3.0% of price |
| RSI (14) | 38.06 | Weak, oversold below 30 | Neutral |
| MACD | -1.98 | Below its signal line | Bearish |
| Stochastic | 25.6 | Middle of its range | Neutral |
| ADX (14) | 14.9 | No clear trend | |
| Williams %R | -91.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -73.2 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −12.2% | Change over 10 sessions | Bearish |
| ATR (14) | $3.15 | Typical daily range, 8.3% of price |
What happened before
See how NVO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How NVO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.
Whale Options FlowPrices may be delayed
90DNo whale options trades in NVO in the last 90 days.
Dark PoolPrices may be delayed
30DNVO Institutional Ownership
Full report →- ▼482 buying vs 716 selling
- ▲Shares held by funds +3.5%
- ▼Funds holding -120
- ▲Superinvestors: 5 added, 0 cut
- ▲Put/call 1.50 to 1.37
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 1,240 | 1,360 | −8.8% |
| In funds' top 10 | 8 | 14 | −42.9% |
| Held by funds | – | – | – |
| New / increased | 93 / 389 | 199 / 463 | −27.2% |
| Reduced / sold out | 508 / 208 | 458 / 122 | +23.4% |
| Put/call ratio | 1.37 | 1.50 | −9.0% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NVO is in one of them and how their past NVO trades turned out.
NVO News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NVO in an article yet. Here's the latest on the wider market.
NVO Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Kevin HernR · OK | Sell | $1K – $15K | Sep 10, 2026 | Sep 25, 2026 | 15 d |
| Kevin HernR · OK | Sell (partial) | $1K – $15K | Aug 31, 2026 | Sep 25, 2026 | 25 d |
| Clifford FranklinR · FL | Buy | $1K – $15K | Aug 26, 2026 | Sep 17, 2026 | 22 d |
| Alan ArmstrongR · OK | Buy | $15K – $50K | Mar 30, 2026 | Jul 21, 2026 | 113 d |
| Lisa McClainR · MI | Sell | $1K – $15K | Oct 31, 2025 | Nov 21, 2025 | 21 d |
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About Novo Nordisk a S
Novo Nordisk is a healthcare company based in Bagsvaerd, Denmark, that discovers, develops, makes and sells pharmaceutical products. Its main focus is obesity and diabetes care, with products including insulin and medicines for weight management and type 2 diabetes. It also sells treatments for rare diseases, mainly growth hormone and haemophilia products. Its customers include patients, doctors and healthcare systems worldwide.
- Headquarters
- Bagsvaerd Denmark, Denmark










